BridgeBio Announces Clinical Collaboration with Amgen to Study BBP-398, a Potentially…
- First clinical combination study of BBP-398 and LUMAKRAS set to evaluate safety and preliminary efficacy in solid tumors with the KRAS G12C mutation PALO ALTO, Calif., Jan. 13, 2022…